RedHill Biopharma Increases At-The-Market Offering Size

RedHill Biopharma Ltd. has filed a prospectus supplement to increase the maximum aggregate offering amount of its American Depositary Shares (ADSs). The ADSs, each representing ten thousand ordinary shares, will be offered and sold from time to time under the existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC, which was established on February 3, 2025. This filing updates the terms of the ongoing at-the-market offering.